Dr. Bernhard Noreisch LL.M. LUTZ | ABEL

Partner | Lawyer | Certified Specialist Lawyer for Commercial and Corporate Law

Dr. Bernhard Noreisch LL.M.

Dr. Bernhard Noreisch LL.M. LUTZ | ABEL

Profile details

Dr Bernhard Noreisch specialises in M&A, venture capital, commercial and corporate law. His clients are mainly medium-sized companies, national and international investors, family offices and young companies, which he regularly assists in M&A transactions and financing rounds.

Besides, Dr Bernhard Noreisch is characterised by his high level of personal commitment, his negotiating skills, his experience, and his solution-oriented advice. Even in highly complex projects, he convinces with competence and his sympathetic and calm manner.

  • Venture capital / private equity
  • Acquisition and sale of companies / M&A
  • Corporate law
  • Commercial and contract law
  • JUVE Handbook continuously since 2016 | 2017: Leading advisor for venture capital
  • JUVE Handbook continuously since 2013 | 2014: Often recommended lawyer
  • Handelsblatt & Best Lawyers: One of the best lawyers for corporate law (2021-2023), venture capital (2021-2023) and private equity (2020 – 2023)
  • Legal 500 Germany (& EMEA) 2016 – 2024 continuously: Recommended lawyer
  • Certified specialist lawyer for commercial and corporate law since 2007
  • Lawyer at LUTZ | ABEL since 2003
  • Admission to the bar, 2003
  • Master's degree at the University of Edinburgh
  • Doctorate (Dr. jur.) and additional training in economics in Bayreuth
  • Law studies in Passau and Bayreuth
  • Neura Robotics on EUR 50 m financing round
  • Bayern Kapital GmbH with its ScaleUp Fonds Bayern on EUR 155 m financing round of Isar Aerospace
  • Majority shareholder of Locoia on sale of locoia GmbH to Aareon Group
  • APK AG in EUR 130 m financing round
  • MIG-Fonds on EUR 128 m series A2 financing round of IQM Finland OY
  • Samsung Catalyst Fund on USD 90 m series B financing round in Ada Health GmbH, 2021
  • MIG-Fonds on USD 20 m series A investment in German Bionic Systems, 2020
  • AMSilk on EUR 29 m series C financing round, 2021
  • Dosimetrics on trade sale to Mirion Technologies, 2020
  • Wachstumsfonds Bayern 2 and Bayern Kapital Innovationsfonds II on EUR 50 m financing round in CatalYm, 2020
  • MIG-Fonds on EUR 39 m financing round in IQM, 2020
  • SHS on investment in Blazejewski MEDI-TECH, 2019


"One of the leading names in venture capital in Germany."

JUVE Handbook since 2016 | 2017


Venture Capital / M&A

LUTZ | ABEL advises in EUR 17 Million Series B round of financing for Temedica

The healthcare start-up Temedica GmbH from Germany announced to have completed a € 17 million Series B financing round.


Venture Capital / M&A

LUTZ | ABEL advises Price f(x) in EUR 23 Mio extension of series B-financing round

The start-up Price f(x) managed to score EUR 23 million within the extension of the series B-financing. Leading investors are Digital + Partners and Bain & Company, while Talis Capital increased their investment. LUTZ | ABEL again acted as company counsel…

Station auf dem Mars

“Bernhard Noreisch is solution-oriented and competent.“

Legal 500 Germany 2023

“Solution-oriented, determined and pleasant.“

Competitor, JUVE Handbook 2022 | 2023

“One of the best lawyers for corporate law, venture capital, private equity.“

Handelsblatt & Best Lawyers 2023

“Bernhard Noreisch is a full professional and practitioner, absolutely solution orientated, deep VC and PE know-how, besides legal knowledge also understanding of the economic context or VC/PE logics, recognised and excellent reputation in the broad VC scene.“

Legal 500 Germany 2022

“Highly committed, very friendly, very competent and reliable, fast response times.“

Legal 500 Germany 2022

“Professionally and personally top and an outstanding negotiator.“

Legal 500 Germany 2020

“Very competent, experienced with a pleasant, calm and professional manner.“

Client, JUVE Handbook 2023 | 2024

“Professionally excellent.“

Competitor, JUVE Handbook 2023 | 2024

“Solution-oriented and determined.“

Competitor, JUVE Handbook 2023 | 2024